Radiation and immunotherapy join forces against early lung cancer

NCT ID NCT03383302

Completed Disease control Sponsor: Royal Marsden NHS Foundation Trust Source: ClinicalTrials.gov ↗

First seen Jul 17, 2026 · Last updated Jul 17, 2026

Summary

This trial investigates whether combining stereotactic body radiotherapy (SBRT), a precise form of radiation, with the immunotherapy drug nivolumab is safe and tolerable for people with early-stage non-small cell lung cancer. Participants receive SBRT followed by nivolumab infusions for up to 20 cycles over about a year. The main focus is on lung side effects, particularly pneumonitis, and how well patients tolerate the treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: stereotactic body radiotherapy (SBRT) and the immunotherapy drug nivolumab (Opdivo)
What this could lead to: If successful, this combination could offer a more effective treatment for early-stage lung cancer with manageable side effects.
What could go wrong: This is an early-phase trial with only 36 participants, so results may not apply broadly. There is a risk of lung inflammation (pneumonitis) from the combination.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER STAGE I are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-SMALL CELL LUNG CANCER STAGE I NON-SMALL CELL LUNG CANCER STAGE II

Contacts and locations

Show contact details

Locations

Royal Marsden Hospital

Sutton, SM2 5PT, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.